Keyphrases
Chemoradiation
100%
Chemoradiotherapy
20%
Durvalumab
100%
Free Survival
6%
Institutional Review
6%
January 2017
6%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Median Time
6%
Multi-institutional
6%
Non-small Cell Lung Cancer Patients
6%
Overall Survival
26%
PACIFIC Trial
6%
Pneumonitis
100%
Prednisone
6%
Progression-free Survival
20%
Radiotherapy
6%
Real-world Outcomes
6%
Rechallenge
20%
Recurring
6%
Stage III Disease
6%
Tumor Factor
6%
Medicine and Dentistry
Chemoradiotherapy
100%
Diseases
6%
Durvalumab
100%
Neoplasm
6%
Non Small Cell Lung Cancer
100%
Overall Survival
26%
Pneumonia
100%
Prednisone
6%
Progression Free Survival
20%
Radiation Therapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Diseases
6%
Durvalumab
100%
Neoplasm
6%
Non Small Cell Lung Cancer
100%
Overall Survival
26%
Pneumonia
100%
Prednisone
6%
Progression Free Survival
20%
Immunology and Microbiology
Durvalumab
100%
Overall Survival
26%
Pneumonitis
100%
Prednisone
6%
Progression Free Survival
20%